Index - 2020

2020 / 2019 / 2018 / 2017



  • Overig
  • Thema-artikelH
  • Let op!LO
  • Nieuw
A
ACE-remmers NSAID's 2020 angiotensine II-antagonisten 2020 corticosteroïden 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020 adaptie CYP2C19 20209-14 PCI 20209-14 beroerte 20209-14 clopidogrel 20209-14 genotypering 20209-14 hartinfarct 20209-14 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 angiotensine II-antagonisten ACE-remmers 2020 NSAID's 2020 corticosteroïden 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020
B
beroerte CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 clopidogrel 20209-14 genotypering 20209-14 hartinfarct 20209-14 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 bias RCT 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 blindering RCT 20201-8 bias 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 borstkanker combinatietherapie 202022-27 hormoontherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 substitutietherapie 202022-27
C
clopidogrel CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 genotypering 20209-14 hartinfarct 20209-14 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 combinatietherapie borstkanker 202022-27 hormoontherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 substitutietherapie 202022-27 confouding by indication RCT 20201-8 bias 20201-8 blindering 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 confounding RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 corticosteroïden ACE-remmers 2020 NSAID's 2020 angiotensine II-antagonisten 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020 covid-19 ACE-remmers 2020 NSAID's 2020 angiotensine II-antagonisten 2020 corticosteroïden 2020 pioglitazone 2020 sars-cov-2 2020 cyp-enzymen CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 CYP2C19 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 genotypering 20209-14 hartinfarct 20209-14 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 CYP2C9 CYP2C19 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 CYP2D6 CYP2C19 202015-20 CYP2C9 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 Cytochrome P450 CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20
E
effect CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 enzymen CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 epidemiologie RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 evidence based medicine RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8
F
farmaco-epidemiologie RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 farmacogenetica CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 farmacokinetiek CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20
G
geneesmiddelen CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 informatiesysteem 202015-20 interactie 202015-20 interacties 202015-20 genotypering CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 hartinfarct 20209-14 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 gerandomiseerd RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8
H
hartinfarct CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 genotypering 20209-14 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 healthy cohort effect RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 hoofdredacteur redactieteam 2020 reorganisatie 2020 hormoontherapie borstkanker 202022-27 combinatietherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 substitutietherapie 202022-27
I
immortal time bias RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 informatiesysteem CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 interactie 202015-20 interacties 202015-20 interactie CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interacties 202015-20 interacties CYP2C19 202015-20 CYP2C9 202015-20 CYP2D6 202015-20 Cytochrome P450 202015-20 cyp-enzymen 202015-20 effect 202015-20 enzymen 202015-20 farmacogenetica 202015-20 farmacokinetiek 202015-20 geneesmiddelen 202015-20 informatiesysteem 202015-20 interactie 202015-20
M
matching RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 menopauze borstkanker 202022-27 combinatietherapie 202022-27 hormoontherapie 202022-27 observationeel 202022-27 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 substitutietherapie 202022-27 methodologie RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8
N
NSAID's ACE-remmers 2020 angiotensine II-antagonisten 2020 corticosteroïden 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020
O
observationeel RCT 20201-8 bias 20201-8 blindering 20201-8 borstkanker 202022-27 combinatietherapie 202022-27 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 hormoontherapie 202022-27 immortal time bias 20201-8 matching 20201-8 menopauze 202022-27 methodologie 20201-8 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 regressieanalyse 20201-8 substitutietherapie 202022-27 surrogaateindpunt 20201-8 validiteit 20201-8 oestrogenen borstkanker 202022-27 combinatietherapie 202022-27 hormoontherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 substitutietherapie 202022-27 oestrogenen en progestagenen borstkanker 202022-27 combinatietherapie 202022-27 hormoontherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen 202022-27 postmenopauzaal 202022-27 substitutietherapie 202022-27
P
PCI CYP2C19 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 genotypering 20209-14 hartinfarct 20209-14 prasugrel 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14 pioglitazone ACE-remmers 2020 NSAID's 2020 angiotensine II-antagonisten 2020 corticosteroïden 2020 covid-19 2020 sars-cov-2 2020 postmenopauzaal borstkanker 202022-27 combinatietherapie 202022-27 hormoontherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 substitutietherapie 202022-27 prasugrel CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 genotypering 20209-14 hartinfarct 20209-14 ticagrelor 20209-14 trombocytenaggregatieremmers 20209-14
R
RCT bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 redactieteam hoofdredacteur 2020 reorganisatie 2020 regressieanalyse RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 surrogaateindpunt 20201-8 validiteit 20201-8 reorganisatie hoofdredacteur 2020 redactieteam 2020
S
sars-cov-2 ACE-remmers 2020 NSAID's 2020 angiotensine II-antagonisten 2020 corticosteroïden 2020 covid-19 2020 pioglitazone 2020 substitutietherapie borstkanker 202022-27 combinatietherapie 202022-27 hormoontherapie 202022-27 menopauze 202022-27 observationeel 202022-27 oestrogenen 202022-27 oestrogenen en progestagenen 202022-27 postmenopauzaal 202022-27 surrogaateindpunt RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 validiteit 20201-8
T
ticagrelor CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 genotypering 20209-14 hartinfarct 20209-14 prasugrel 20209-14 trombocytenaggregatieremmers 20209-14 trombocytenaggregatieremmers CYP2C19 20209-14 PCI 20209-14 adaptie 20209-14 beroerte 20209-14 clopidogrel 20209-14 genotypering 20209-14 hartinfarct 20209-14 prasugrel 20209-14 ticagrelor 20209-14
V
validiteit RCT 20201-8 bias 20201-8 blindering 20201-8 confouding by indication 20201-8 confounding 20201-8 epidemiologie 20201-8 evidence based medicine 20201-8 farmaco-epidemiologie 20201-8 gerandomiseerd 20201-8 healthy cohort effect 20201-8 immortal time bias 20201-8 matching 20201-8 methodologie 20201-8 observationeel 20201-8 regressieanalyse 20201-8 surrogaateindpunt 20201-8